Virtuix Holdings Inc. — Form 8-K
Filed August 20, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Virtuix reported Q1 FY2027 (ended June 30, 2026) with new Omni One orders up 72% year-over-year and ~150% since the Meta Quest launch. Revenue declined 26% to $0.8M (from $1.0M prior year) due to completion of legacy backlog, but gross margin expanded to 30% from 17%. Net loss widened to $7.2M from $2.3M, driven by $4.0M in non-cash charges (primarily $2.5M interest expense/debt discount amortization on convertible notes). Cash fell to $7.4M from $9.5M; stockholders' equity swung to a $3.1M deficit. Key wins: U.S. Marine Corps Infantry Fireteam Trainer pilot delivery expected Q4 2026; first Omni One Enterprise sale to Tesla Optimus; NASA Moon/Mars Analog mission selection; Sirica Therapeutics autism therapy partnership (targeting ~100 treatment centers). Company pursuing defense M&A targets with $10M–$50M revenue.
Why this rating
Strong order momentum and multi-vertical expansion (defense, enterprise, healthcare, Meta) offset near-term revenue decline and widening losses. At $14.8M asset base, order growth and enterprise/defense traction are material; however, cash burn ($2M/quarter), $10.7M debt load, and path-to-profitability uncertainty temper upside.
See more from August 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.